Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval
Open accessPublished version of a preprint
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Despite strong vetting for disease activity, only 10% of candidate new molecular entities in early stage clinical trials are eventually approved. Analyzing historical pipeline data, Nelson et al. 2015 (Nat. Genet.) concluded pipeline drug targets with human genetic evidence of disease association are twice as likely to lead to approved drugs. Taking advantage of recent clinical development advances and rapid growth in GWAS datasets, we extend the original work using updated data, test whether genetic evidence predicts future successes and introduce statistical models adjusting for target and indication-level properties. Our work confirms drugs with genetically supported targets were more likely to be successful in Phases II and III. When causal genes are clear (Mendelian traits and GWAS associations linked to coding variants), we find the use of human genetic evidence increases approval by greater than two-fold, and, for Mendelian associations, the positive association holds prospectively. Our findings suggest investments into genomics and genetics are likely to be beneficial to companies deploying this strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig 1 Estimated effect of evidence from human genetic studies on the probability of advancing in clinical development. A: Partitioning Pharmaprojects, OMIM, and GWAS Catalog into training data available to Nelson et al. 2015 and validation sets. We use validation set Pipeline Progression, consisting of target-indication pairs assigned a clinical phase in 2013, to determine whether gene target-indication pairs with genetic evidence were more likely to advance to the next pipeline phase from 2013-2018. Pharmaprojects target-indication pairs absent from or assigned an unknown clinical phase in the Nelson et al. dataset form the New Pipeline replication set. Pharmaprojects target-indication pairs approved prior to 2013 or with unknown phase in our dataset are not part of any replication set. B: Our estimates of the effect of genetic evidence on gene target-indication pair progression compared to values reported by Nelson et al. 2015 [3] in validation sets New Pipeline (drugs and indications > 2013, 2013 inactive drugs) New Genetic (only new genetic information > 2013) Pipeline Progression, and in the full updated dataset (Full Data). Estimates falling close to the identity line (shown in black) are consistent between the two analyses.](https://figures.cochat.ai/paper-figures/fbfe5599a9364dd7aab42f07a9e12b6a/are-drug-targets-with-genetic-support-twice-as-likely-to-be-approved-revised-figure-1.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is supported by drug candidates with genetically supported targets being significantly more likely to progress through phased clinical trials (9, 10).”
From Identification of human gene research articles with wrongly identified nucleotide sequences (2022) · cites this paper as [10]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A global reference for human genetic variation
The 1000 Genomes Project Consortium, authors, C., Auton, A., Abecasis, G. R., Steering committee, Altshuler, D. M., Durbin, R. M., Abecasis, G. R., Bentley, D. R., Chakravarti, A., et al. (2015) · Nature · doi:10.1038/nature15393 · Cited by 18,247
Cingolani, P., Platts, A., Wang, L. L., Coon, M., Nguyen, T., Wang, L., Land, S. J., Lu, X., & Ruden, D. M. (2012) · Fly · doi:10.4161/fly.19695 · Cited by 11,816
The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in humans
The GTEx Consortium, Ardlie, K. G., Deluca, D. S., Segrè, A. V., Sullivan, T. J., Young, T. R., Gelfand, E. T., Trowbridge, C. A., Maller, J. B., Tukiainen, T., et al. (2015) · Science · doi:10.1126/science.1262110 · Cited by 5,062
An Information-Theoretic Definition of Similarity
Lin, D. (1998) · International Conference on Machine Learning · Cited by 4,697
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
The NHGRI GWAS Catalog, a curated resource of SNP-trait associations
Welter, D., MacArthur, J., Morales, J., Burdett, T., Hall, P., Junkins, H., Klemm, A., Flicek, P., Manolio, T., Hindorff, L., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1229 · Cited by 2,707
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
Watanabe, S. (2010) · arXiv (Cornell University) · doi:10.48550/arxiv.1004.2316 · Cited by 2,226
Research works printed but not linked: 1
- J MacArthur, 2016, The new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog), Nucleic Acids Research, 45, D896, 10.1093/nar/gkw1133 · DOI · Paper page
Cited by
Items 201–300 of 648
Genetic ablation of Gpnmb does not alter synuclein-related pathology
Brendza, R. P., Lin, H., Stark, K. L., Foreman, O., Tao, J., Pierce, A. A., Ngu, H., Shen, K., Easton, A. E., Bhangale, T., et al. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105494 · Cited by 17
Genetic Determinants of the Acute Respiratory Distress Syndrome
Suarez-Pajes, E., Tosco-Herrera, E., Ramirez-Falcon, M., González-Barbuzano, S., Hernández-Beeftink, T., Guillén‐Guío, B., Villar, J., & Flores, C. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12113713 · Cited by 18
Nuytemans, K., Franzen, S., Broce, I., Caramelli, P., Ellajosyula, R., Finger, E. C., Gupta, V. B., Gupta, V., Illán‐Gala, I., Loi, S. M., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14312 · Cited by 17
Lessard, S., Chao, M. J., Reis, K., FinnGen, Rajpal, D. K., Shankara, S., Sloane, J., Palta, P., Klinger, K. W., de Rinaldis, E., et al. (2024) · BMC Genomics · doi:10.1186/s12864-024-10971-2 · Cited by 22
Pozarickij, A., Said, S., Lin, K., Morris, S., Edris, A., Iona, A., Kartsonaki, C., Wright, N., Yao, P., Fry, H., et al. (2023) · doi:10.1101/2023.11.13.23298365 · Cited by 16
Jung, J., Lu, Z., de Smith, A. J., & Mancuso, N. (2023) · Human Molecular Genetics · doi:10.1093/hmg/ddad174 · Cited by 17
Alda-Catalinas, C., Ibarra-Soria, X., Flouri, C., Gordillo, J. E., Cousminer, D. L., Hutchinson, A., Sun, B., Pembroke, W. G., Ullrich, S., Krejčí, A., et al. (2024) · Genome biology · doi:10.1186/s13059-024-03176-z · Cited by 20
Network analysis of genome-wide association studies for drug target prioritisation
Barrio‐Hernandez, I., & Beltrão, P. (2022) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2022.102206 · Cited by 19
Cross-platform proteomics to advance genetic prioritisation strategies
Pietzner, M., Wheeler, E., Carrasco-Zanini, J., Kerrison, N. D., Oerton, E., Koprulu, M., Luan, J., Hingorani, A. D., Williams, S. A., Wareham, N. J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.18.435919 · Cited by 15
Drug Gene-Set Analysis Identifies Established and Emerging Therapeutic MechanismsPreprint
Bell, N. Y., Uffelmann, E., van Walree, E. S., Schipper, M., Heilbron, K., de Leeuw, C., & Posthuma, D. (2022) · medRxiv · doi:10.1101/2022.09.06.22279660 · Cited by 16
An in-depth review of AI-powered advancements in cancer drug discovery
Le, M. H. N., Nguyen, P. K., Nguyen, T. P. T., Nguyen, H. Q., Tam, D. N. H., Huynh, H. H., Huynh, P. K., & Le, N. Q. K. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167680 · Cited by 15
Manuel, A. M., Dai, Y., Jia, P., Freeman, L. A., & Zhao, Z. (2022) · Human Molecular Genetics · doi:10.1093/hmg/ddac265 · Cited by 24
Molecular Landscape of Tourette’s Disorder
Widomska, J., Witte, W. D., Buitelaar, J. K., Glennon, J. C., & Poelmans, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021428 · Cited by 16
Henne, S. K., Nöthen, M. M., & Heilmann-Heimbach, S. (2023) · Medizinische Genetik · doi:10.1515/medgen-2023-2003 · Cited by 23
Selecting the right therapeutic target for kidney disease
Buvall, L., Menzies, R. I., Williams, J. H., Woollard, K. J., Kumar, C., Granqvist, A., Fritsch, M., Féliers, D., Reznichenko, A., Gianni, D., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.971065 · Cited by 17
New directions in psychiatric drug development: promising therapeutics in the pipeline
Brady, L. S., Lisanby, S. H., & Gordon, J. A. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2224555 · Cited by 15
AI Enabled Precision Medicine: Patient Stratification, Drug Repurposing and Combination Therapies
Gardner, S., Das, S., & Taylor, K. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.92594 · Cited by 23
A systematic comparison of computational methods for expression forecasting
Kernfeld, E., Yang, Y., Weinstock, J. S., Battle, A., & Cahan, P. (2023) · doi:10.1101/2023.07.28.551039 · Cited by 15
Qu, S., Zhou, X., Wang, Z., Yi, W., Zhou, H., Zhang, X., Zhu, Q., Wang, Y., Yang, Q., Jiang, L., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02314-6 · Cited by 14
Levin, M. G., Huffman, J. E., Verma, A., Sullivan, K. A., Rodriguez, A., Kainer, D., Garvin, M. R., Lane, M. J., Cashman, M., Miller, J., et al. (2023) · Nature Cardiovascular Research · doi:10.1038/s44161-022-00196-5 · Cited by 15
Discovering Biological Mechanisms of Exceptional Human Health Span and Life SpanPreprint
Milman, S., & Barzilai, N. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041204 · Cited by 14
The broken Alzheimer’s disease genome
Roque, C. G., Phatnani, H. P., & Hengst, U. (2024) · Cell Genomics · doi:10.1016/j.xgen.2024.100555 · Cited by 15
Muiño, E., Cárcel‐Márquez, J., Llucià‐Carol, L., Gallego-Fábrega, C., Cullell, N., Lledós, M., Martín-Campos, J. M., Villatoro-González, P., Sierra‐Marcos, A., Ros‐Castelló, V., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000209666 · Cited by 13
Linking Genome-Wide Association Studies to Pharmacological Treatments for Psychiatric Disorders
Arnatkevičiūtė, A., Fornito, A., Tong, J., Pang, K. C., Fulcher, B., & Bellgrove, M. A. (2024) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2024.3846 · Cited by 13
Konieczny, M. J., Omarov, M., Zhang, L., Malik, R., Richardson, T. G., Baumeister, S., Bernhagen, J., Dichgans, M., & Georgakis, M. K. (2025) · Communications Biology · doi:10.1038/s42003-025-07453-w · Cited by 18
Multi-omics analysis in primary T cells elucidates mechanisms behind disease-associated genetic loci
Shi, C., Zhao, D., Butler, J. S., Frantzeskos, A., Rossi, S., Ding, J., Ferrazzano, C., Wynn, C., Hum, R. M., Richards, E., et al. (2025) · Genome biology · doi:10.1186/s13059-025-03492-y · Cited by 15
Kalailingam, P., Rannikmäe, K., Hausman‐Kedem, M., Musolino, P. L., & Ruigrok, Y. M. (2025) · Stroke · doi:10.1161/strokeaha.124.045182 · Cited by 13
Mendelian Randomisation: Concepts, Opportunities, Challenges, and Future Directions
de Ruiter, S. C., Tschiderer, L., Grobbee, D. E., Willeit, P., den Ruijter, H. M., Schmidt, A. F., & Peters, S. A. E. (2025) · Global Heart · doi:10.5334/gh.1438 · Cited by 17
Delobel, V., Grenier, C., Boulestreau, R., Rubin, S., Vaurs, J., Jaspard‐Vinassa, B., Casas, E., Busson, M., Combrouze, C., Proust, C., et al. (2026) · Communications Biology · doi:10.1038/s42003-026-09628-5 · Cited by 15
Genetic variation, adipokines, and cardiometabolic disease
Metz, S., Huang, L. O., & Kilpeläinen, T. O. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.04.006 · Cited by 14
Prince, C., Mitchell, R. E., & Richardson, T. G. (2021) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2021.10.003 · Cited by 13
Rare and undiagnosed diseases: From disease-causing gene identification to mechanism elucidation
Wang, G., Xu, Y., Wang, Q., Chai, Y., Sun, X., Yang, F., Zhang, J., Wu, M., Liao, X., Yu, X., et al. (2022) · Fundamental Research · doi:10.1016/j.fmre.2022.09.002 · Cited by 15
The support of genetic evidence for cardiovascular risk induced by antineoplastic drugs
Cui, H. S., Zuo, S., Liu, Z., Liu, H., Wang, J., You, T., Zheng, Z., Zhou, Y., Qian, X., Yao, H., et al. (2020) · Science Advances · doi:10.1126/sciadv.abb8543 · Cited by 13
David, S., Dorado, G., Duarte, E. L., David-Bosne, S., Trigueiro-Louro, J. M., & Rebelo‐de‐Andrade, H. (2022) · Immunogenetics · doi:10.1007/s00251-022-01261-w · Cited by 13
Wang, K., Yi, H., Wang, Y., Jin, D., Zhang, G., & Mao, Y. (2024) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2024.05.007 · Cited by 13
Song, W., Li, Y., Yao, Y., Sun, S., Guan, X., & Wang, B. (2024) · BMC Cancer · doi:10.1186/s12885-024-12449-6 · Cited by 13
Proprotein convertase subtilisin/kexin type 9 as a drug target for abdominal aortic aneurysm
Golledge, J., Lu, H. S., & Shah, S. H. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000945 · Cited by 12
Leblanc, F., Jin, X., Kang, K., Lee, C. J. M., Xu, J., Xuan, L., Ma, W., Belhaj, H., Benzaki, M., Mehta, N., et al. (2024) · iScience · doi:10.1016/j.isci.2024.110660 · Cited by 13
Delabays, B., Trajanoska, K., Walonoski, J., & Mooser, V. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.000750 · Cited by 13
High-throughput identification of functional regulatory SNPs in systemic lupus erythematosus
Wang, Q., Kim, T., Martínez‐Bonet, M., Aguiar, V. R. C., Sim, S., Cui, J., Sparks, J. A., Chen, X., Todd, M., Wauford, B., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50710-5 · Cited by 16
Gordillo‐Marañón, M., Schmidt, A. F., Warwick, A., Tomlinson, C., Ytsma, C. R., Engmann, J., Torralbo, A., Maclean, R., Sofat, R., Langenberg, C., et al. (2024) · Communications Medicine · doi:10.1038/s43856-024-00625-5 · Cited by 12
Drug repurposing opportunities for breast cancer and seven common subtypes
Lin, Y., Wang, S., Zhang, Y., She, J., Zhang, Y., Zhao, R., Qi, Z., Yang, Q., Zhang, L., & Yang, Q. (2024) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2024.106652 · Cited by 13
Patient-derived organoids inform pharmacogenomic vulnerabilities in liver cancer
Wong, A. M., Huang, H., Wong, A. M. G., Leung, H. H. W., Cheung, W. W. Y., Lam, Y. K., Ding, X., Zhang, L., Chu, C., Liu, Y., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101426 · Cited by 19
mTOR pathway diseases: challenges and opportunities from bench to bedside and the mTOR node
Ritter, L. M., Annear, N. M. P., Baple, E. L., Ben-Chaabane, L. Y., Bódi, I., Brosson, L., Cadwgan, J., Coslett, B., Crosby, A. H., Davies, D. M., et al. (2025) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-025-03740-1 · Cited by 13
deGoma, E. M., Walsh, J., & Georgakis, M. K. (2025) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.125.005103 · Cited by 17
Portelli, M. A., Rakkar, K., Hu, S., Guo, Y., Adcock, I. M., & Sayers, I. (2021) · Frontiers in Allergy · doi:10.3389/falgy.2021.738741 · Cited by 12
Analytical Considerations of Large-Scale Aptamer-Based Datasets for Translational Applications
Jiang, W. M., Jones, J. C., Shankavaram, U. T., Sproull, M. T., Camphausen, K. A., & Krauze, A. V. (2022) · Cancers · doi:10.3390/cancers14092227 · Cited by 12
New Drug Targets and Preclinical Modelling Recommendations for Treating Acute Myocardial Infarction
Cao, Y., Redd, M. A., Chen, F., Mizikovsky, D., Li, X., Macdonald, P. S., King, G. F., & Palpant, N. J. (2023) · Heart Lung and Circulation · doi:10.1016/j.hlc.2022.12.015 · Cited by 13
Narganes-Carlón, D., Crowther, D. J., & Pearson, E. R. (2023) · Scientific Reports · doi:10.1038/s41598-023-35597-4 · Cited by 16
Rajasundaram, S., Zebardast, N., Mehta, P. A., Khawaja, A. P., Warwick, A., Duchinski, K., Burgess, S., Gill, D., Segrè, A. V., & Wiggs, J. L. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04737-9 · Cited by 14
Poppelaars, F., da Costa, M. G., Eskandari, S. K., Damman, J. J., & Seelen, M. A. (2021) · Scientific Reports · doi:10.1038/s41598-021-95714-z · Cited by 15
Genome editing to define the function of risk loci and variants in rheumatic disease
Baglaenko, Y., Macfarlane, D., Marson, A., Nigrovic, P. A., & Raychaudhuri, S. (2021) · Nature Reviews Rheumatology · doi:10.1038/s41584-021-00637-8 · Cited by 12
Improving Translational Paradigms in Drug Discovery and Development
Williams, M. J. (2021) · Current Protocols · doi:10.1002/cpz1.273 · Cited by 12
Gao, Y., Felsky, D., Reyes‐Dumeyer, D., Sariya, S., Rentería, M. A., Ma, Y., Klein, H., Cosentino, S., Jager, P. L. D., Bennett, D. A., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12524 · Cited by 12
Das, S., Taylor, K., Beaulah, S. A., & Gardner, S. (2022) · Patterns · doi:10.1016/j.patter.2022.100496 · Cited by 18
Systemic neuro-dysregulation in depression: Evidence from genome-wide association
Tubbs, J. D., Ding, J., Baum, L., & Sham, P. C. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.08.007 · Cited by 12
Organization of gene programs revealed by unsupervised analysis of diverse gene–trait associations
Mizikovsky, D., Naval Sanchez, M., Nefzger, C. M., Cuellar Partida, G., & Palpant, N. J. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac413 · Cited by 12
Organisation of gene programs revealed by unsupervised analysis of diverse gene-trait associations
(2022) · doi:10.1101/2022.04.07.487559 · Cited by 12
Hou, W., Watson, C., Cecconie, T., Bolaki, M. N., Brady Jennifer, J., Lu, Q., Gatto, G. J. J., & Day, T. A. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107353 · Cited by 11
Namba, S., Iwata, M., Nureki, S., Otani, N. Y., & Yamanishi, Y. (2025) · Nature Communications · doi:10.1038/s41467-025-58464-4 · Cited by 12
From variants to mechanisms: Neurogenomics in the post-GWAS era
Margolis, M. P., Tang, M., Gagliardi, M., Wen, C. H., Wu, Y., Wray, N. R., Ziller, M. J., & Gandal, M. J. (2025) · Neuron · doi:10.1016/j.neuron.2025.10.014 · Cited by 16
Poppelaars, F., da Costa, M. G., Faria, B., Eskandari, S. K., Damman, J. J., & Seelen, M. A. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab175 · Cited by 11
Integration of Real‐World Data and Genetics to Support Target Identification and Validation
Davitte, J., Stott‐Miller, M., Ehm, M. G., Cunnington, M. C., & Reynolds, R. F. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2477 · Cited by 12
A cross-disease, pleiotropy-driven approach for therapeutic target prioritization and evaluation
Bao, C., Tan, T., Wang, S., Gao, C., Lu, C., Yang, S., Diao, Y., Jiang, L., Jing, D., Chen, L., et al. (2024) · Cell Reports Methods · doi:10.1016/j.crmeth.2024.100757 · Cited by 13
Estimating colocalization probability from limited summary statistics
King, E. A., Dunbar, F., Davis, J. W., & Degner, J. F. (2021) · BMC Bioinformatics · doi:10.1186/s12859-021-04170-z · Cited by 13
Self-citationAI models and the future of genomic research and medicine: True sons of knowledge?
König, H., Frank, D., Baumann, M., & Heil, R. (2021) · BioEssays · doi:10.1002/bies.202100025 · Cited by 11
Fang, H., & Jiang, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.687291 · Cited by 12
Jurrjens, A. W., Seldin, M. M., Giles, C., Meikle, P. J., Drew, B. G., & Calkin, A. C. (2023) · eLife · doi:10.7554/elife.86139 · Cited by 11
Stroke Genetics, Genomics, and Precision Medicine
Debette, S., & Paré, G. (2024) · Stroke · doi:10.1161/strokeaha.123.044212 · Cited by 12
Wiegrebe, S., Gorski, M., Herold, J. M., Stark, K. J., Thorand, B., Gieger, C., Böger, C. A., Schödel, J., Hartig, F., Chen, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54483-9 · Cited by 17
Fang, H. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac379 · Cited by 10
Oriented Crossover in Genetic Algorithms for Computer Networks Optimization
Rabee, F., & Hussain, Z. M. (2023) · Information · doi:10.3390/info14050276 · Cited by 10
Application of Genomic Data in Translational Medicine During the Big Data Era
Zhang, Y., Yu, J. M., Xie, X., Jiang, F., & Wu, C. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2901007 · Cited by 10
Li, X., Jiang, L., Xue, C., Li, M. J., & Li, M. (2022) · eLife · doi:10.7554/elife.70779 · Cited by 11
Associations of Polygenic Risk Score for Late-Onset Alzheimer's Disease With Biomarkers
Li, Q., Lv, X., Jin, F., Liao, K., Gao, L., & Xu, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.849443 · Cited by 13
Coming of Age: Human Genomics and the Cancer–Immune Set Point
Hammer, C., & Mellman, I. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-1017 · Cited by 11
Ueda, M., Fukui, K., Kamatani, N., Kamitsuji, S., Matsuo, A., Sasase, T., Nishiu, J., & Matsushita, M. (2023) · Journal of Human Genetics · doi:10.1038/s10038-023-01168-8 · Cited by 10
Identifying Novel Psoriatic Disease Drug Targets Using a Genetics-Based Priority Index Pipeline
Bui, A., Liu, J., Hong, J. J., Hadeler, E. K., Mosca, M., Brownstone, N. D., & Liao, W. J. (2021) · Journal of Psoriasis and Psoriatic Arthritis · doi:10.1177/24755303211026023 · Cited by 12
Study profile: the Genetics of Glaucoma Study
Gharahkhani, P., He, W., Díaz‐Torres, S., Wu, Y., Ingold, N., Yu, R., Seviiri, M., Ong, J., Law, M. H., Craig, J. E., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-068811 · Cited by 10
Boovarahan, S. R., Balu, K., Prem, P. N., Sivakumar, B., & Kurian, G. A. (2023) · Functional & Integrative Genomics · doi:10.1007/s10142-023-01257-z · Cited by 9
How to translate genetic findings into clinical applications in spondyloarthritis?
Frison, E., Bréban, M., & Costantino, F. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1301735 · Cited by 9
Using Mendelian randomization provides genetic insights into potential targets for sepsis treatment
Xia, R., Sun, M., Yin, J., Zhang, X., & Li, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-58457-1 · Cited by 9
Jiang, R., Huang, W., Qiu, X., Chen, J., Luo, R., Zeng, R., Tong, S., Lyu, Y., Sun, P., Lian, Q., et al. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae353 · Cited by 10
Druggable targets for Parkinson’s disease: transcriptomics based Mendelian randomization study
Lyu, Q., Chen, R., Qiu, Z., Wang, C., & Liu, R. (2024) · Scientific Reports · doi:10.1038/s41598-024-77401-x · Cited by 9
Lee, S., Han, M., Moon, S., Kim, K., An, W. J., Ryu, H., Oh, K., & Park, S. K. (2022) · Metabolites · doi:10.3390/metabo12111139 · Cited by 9
The Power of Clinical Diagnosis for Deciphering Complex Genetic Mechanisms in Rare Diseases
Shu, L., Maroilley, T., & Tarailo‐Graovac, M. (2023) · Genes · doi:10.3390/genes14010196 · Cited by 11
Tobias, J. H., Duncan, E. L., Kague, É., Hammond, C. L., Gregson, C. L., Bassett, D., Williams, G. R., Min, J. L., Gaunt, T. R., Karasik, D., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.630875 · Cited by 9
Drug Repurposing in Oncology, an Attractive Opportunity for Novel Combinatorial Regimens
Falvo, P., Orecchioni, S., Roma, S., Raveane, A., & Bertolini, F. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327999200817104912 · Cited by 11
O’Mara, T. A., Batra, J., & Glubb, D. M. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01038 · Cited by 10
Stanzick, K. J., Stark, K. J., Gorski, M., Schödel, J., Krüger, R., Kronenberg, F., Warth, R., Heid, I. M., & Winkler, T. W. (2023) · BMC Bioinformatics · doi:10.1186/s12859-023-05472-0 · Cited by 10
Hypergraph-based Gene Ontology Embedding for Disease Gene Prediction
Wang, T., Xu, H., Zhang, R., Xiao, Y., Peng, J., & Shang, X. (2022) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm55620.2022.9995140 · Cited by 8
Genetic and molecular biomarkers for geographic atrophy
Riley-Gillis, B. M., Huh, H., Shen, J., & den Hollander, A. I. (2023) · Acta Ophthalmologica · doi:10.1111/aos.15803 · Cited by 8
Rodent genetically modified models of glaucoma
Loo, Y., Chan, A. S. Y., Khor, C. C., Aung, T., & Wang, Z. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101229 · Cited by 8
GETdb: A comprehensive database for genetic and evolutionary features of drug targets
Zhang, Q., He, Y., Lu, Y.-P., Wei, Q.-H., Zhang, H., & Yuan, Q. (2024) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2024.04.006 · Cited by 9
Leveraging large-scale biobanks for therapeutic target discovery
Ferolito, B. R., Dashti, H., Giambartolomei, C., Peloso, G. M., Golden, D. J., Gravel-Pucillo, K., Rasooly, D., Horimoto, A. R. V. R., Matty, R., Gaziano, L., et al. (2025) · Human Genetics and Genomics Advances · doi:10.1016/j.xhgg.2025.100556 · Cited by 10
Anderson, E. L., Williams, D. M., Walker, V. M., & Davies, N. M. (2022) · Scientific Reports · doi:10.1038/s41598-022-05225-8 · Cited by 8
Cohen, A. L. (2022) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-022-09433-1 · Cited by 8
Facal, F., Arrojo, M., Paz, E., Páramo, M., & Costas, J. (2022) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13444 · Cited by 9
LRRK2 ‐Targeting Therapies March Through the Valley of Death
West, A. B., & Schwarzschild, M. A. (2023) · Movement Disorders · doi:10.1002/mds.29343 · Cited by 9
Ji, Y., Zhao, J., Gong, J., Sedlazeck, F. J., & Fan, S. (2024) · Molecular Genetics and Genomics · doi:10.1007/s00438-024-02158-x · Cited by 8
Metadata
- Authors
- King, E. A., Davis, J. W., & Degner, J. F.
- Affiliations
- AbbVie (United States) (US)
- Corresponding author
- King, Emily A.
- Venue
- PLOS Genetics
- Publisher
- Public Library of Science (PLoS)
- Published
- 2019-12-12
- Volume
- 15
- Issue
- 12
- Pages
- e1008489
- ISSN
- 1553-7390 (ISSN-L)
- 1553-7404
- PMC
- PMC6907751
- OpenAlex
- W2995245946
- Cited by
- 649
- References
- 40
- Citations by year
- 2026: 71 · 2025: 97 · 2024: 132 · 2023: 118 · 2022: 92 · 2021: 85 · 2020: 47 · 2019: 6
- FWCI
- 34.63
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Genetics (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- drug approval, therapeutic target, genetic evidence, drug development pipeline, new chemical entities, monogenic disorders, genome-wide association study, coding variants, drug development investment
- MeSH terms
- Pharmacogenomic Variants, Humans, Phenotype, Models, Statistical, Drug Approval, Genetic Predisposition to Disease, Genomics, Databases, Genetic, Quantitative Trait Loci, Genome-Wide Association Study, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.